Highlights Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1.62 ^USD	-4.71%		-7.43%	-39.33%

26/06	Sector Update: Health Care Stocks Softer Late Afternoon	MT
26/06	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Softer Late Afternoon	27/06	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	27/06	MT
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise	26/06	MT
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions	26/06	CI
Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib?s Potential as Precision Medicine for Cancer	03/06	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000	15/05	MT
Top Midday Gainers	01/05	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	30/04	MT
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	30/04	DJ
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	01/04	CI
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	20/03	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
North American Morning Briefing : S&P 500 Futures -2-	20/12	DJ
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions	18/12	CI
Reverse Split: 1 of 15	18/12	FA
Earnings Flash (CYCC) CYCLACEL Reports Q3 Revenue $16,000	14/11	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	14/11	CI
Earnings Flash (CYCC) CYCLACEL Posts Q2 Revenue $373,000	10/23/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Highlights

Filters